Recent results raise hope of new "broad, pan-tumor platform" like Keytruda. The emerging drugs are bispecific antibodies that ...

The FDA has accepted a BLA for treatment with RP1 in combination with Opdivo for patients with advanced melanoma who have ...

Among patients with advanced gastric and GEJ cancer, or esophageal adenocarcinoma, treatment with first-line Opdivo and chemo demonstrated deep responses.

Shares of Exicure Inc. surged more than 25% on Thursday, reaching levels last seen over three weeks ago, following the ...

Replimune Group, Inc. REPL announced that the FDA has accepted the biologics license application (BLA) for its lead pipeline ...

Merck and AstraZeneca have seen their share prices surge after Bristol-Myers Squibb suffered a major setback with Opdivo in non-small cell lung cancer (NSCLC). BMS announced on Friday that Opdivo ...

In a report released today, Robert Burns from H.C. Wainwright reiterated a Buy rating on Replimune Group (REPL – Research Report), with a price ...

An FDA committee’s September 2024 vote to limit the use of Merck’s Keytruda and BMS’ Opdivo in stomach and esophageal cancers ...

H.C. Wainwright analyst Robert Burns raised the firm’s price target on Replimune (REPL) to $21 from $17 and keeps a Buy rating on the shares. The firm expects a “relatively uneventful” FDA review ...

Nivolumab plus chemotherapy improved long-term survival in Chinese patients with advanced gastric, GEJ, or esophageal cancer.

Halozyme (HALO) announced that Bristol Myers Squibb (BMY) received FDA approval for Opdivo Qvantig co-formulated with Halozyme’s Enhanze drug delivery technology for subcutaneous use in most ...

Medicare typically covers Opdivo. With Original Medicare, if you get it as an outpatient infusion, you pay a 20% copay each time after meeting your Part B deductible. Opdivo (nivolumab ...